XLO - Xilio Therapeutics, Inc.
8.57
0.220 2.567%
Share volume: 40,392
Last Updated: 04-17-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.19%
PREVIOUS CLOSE
CHG
CHG%
$8.35
0.22
0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2024 | 08-08-2024 | 11-07-2024 | 03-11-2025 | 05-08-2025 | 11-13-2025 | 03-23-2026 | |
| Assets | ||||||||
| Total Assets | 82.609 M | 89.873 M | 74.658 M | 71.075 M | 103.716 M | 133.694 M | 154.685 M | |
| Current Assets | 69.185 M | 78.008 M | 63.309 M | 60.234 M | 93.200 M | 124.089 M | 145.027 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 17.500 M | 5.000 M | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 33.980 M | 74.949 M | 61.259 M | 55.291 M | 89.073 M | 103.764 M | 137.531 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 5.542 M | 5.137 M | 4.845 M | 4.472 M | 4.289 M | 3.679 M | 3.892 M | |
| Other Assets | 7.882 M | 6.728 M | 6.504 M | 6.369 M | 6.227 M | 5.926 M | 5.766 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 82.609 M | 89.873 M | 74.658 M | 71.075 M | 103.716 M | 133.694 M | 154.685 M | |
| Total liabilities | 56.844 M | 56.457 M | 53.684 M | 53.477 M | 93.016 M | 141.789 M | 119.412 M | |
| Total current liabilities | 31.582 M | 38.641 M | 38.022 M | 27.261 M | 47.637 M | 56.401 M | 56.273 M | |
| Accounts Payable | 746.000 K | 1.264 M | 972.000 K | 2.574 M | 2.275 M | 2.300 M | 3.168 M | |
| Other liabilities | 7.863 M | 7.566 M | 7.263 M | 6.954 M | 6.638 M | 59.890 M | 42.504 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 7.863 M | 7.566 M | 7.263 M | 6.954 M | 6.638 M | 59.890 M | 42.504 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 25.765 M | 33.416 M | 20.974 M | 17.598 M | 10.700 M | -8.095 M | 35.273 M | |
| Common stock | 368.480 M | 390.056 M | 391.634 M | 401.351 M | 407.718 M | 421.054 M | 454.062 M | |
| Retained earnings | -342.715 M | -356.640 M | -370.660 M | -383.753 M | -397.018 M | -429.149 M | -418.789 M |